The classic website will no longer be available as of June 25, 2024. Please use the modernized ClinicalTrials.gov.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Auditory and Visual Noise as Possible Non-pharmacological Treatment of ADHD in School Children

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT06057441
Recruitment Status : Recruiting
First Posted : September 28, 2023
Last Update Posted : March 1, 2024
Sponsor:
Collaborator:
Lund University
Information provided by (Responsible Party):
Emma Claesdotter-Knutsson, Region Skane

Tracking Information
First Submitted Date  ICMJE September 12, 2023
First Posted Date  ICMJE September 28, 2023
Last Update Posted Date March 1, 2024
Actual Study Start Date  ICMJE October 1, 2023
Estimated Primary Completion Date June 2024   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: September 21, 2023)
Inhibitory control [ Time Frame: Six months ]
Inhibitory control is the ability to suppress nonproductive behaviors and cognitive processing and will be measured through the eye tracking tasks (PF and MGS) in the study.
Original Primary Outcome Measures  ICMJE Same as current
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: September 21, 2023)
  • SNAP [ Time Frame: Six months ]
    The SNAP rating scale is an assessment tool for traits of hyperactivity and inattention in ADHD (Swanson et al., 2012). Will be filled out by legal guardians of the participants.
  • 5-15R [ Time Frame: Six months ]
    The 5-15R assessment is aimed at legal guardians of the participants and consists of 181 claims that evaluates motor and cognitive performance in children aged 5 to 15 as well as a psychiatric assessment (Kadesjö et al., 2017)
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Auditory and Visual Noise as Possible Non-pharmacological Treatment of ADHD in School Children
Official Title  ICMJE Auditory and Visual Noise as Possible Non-pharmacological Treatment of ADHD in School Children
Brief Summary

The goal of this study is to compare the influence of visual and auditory white noise on performance in children with attention deficit hyperactivity disorder (ADHD). The main questions it aims to answer are:

  • Can auditory white noise stimulation affect cognitive performance?
  • Can visual white pixel noise affect cognitive performance? Participants will complete two eye tracking tasks under different sensory noise stimulation.

Researchers will compare the ADHD group with a group of typically developing children to see if the noise influences the groups differently and if it has the potential to affect the performance of the ADHD group, to reach the level of the control group.

Detailed Description

Attention Deficit Hyperactivity disorder (ADHD) is one of the most frequent childhood disorders with an estimated prevalence of about 5%. Multimodal treatment is recommended in both national and international guidelines of ADHD care, but most patients only receive pharmacological treatment, sometimes in combination with parent training. As such, the most common treatment approach today is stimulant medication, e.g., methylphenidate. However, there are insufficient understanding about several aspects of medical treatment. For example, it is not evident that medication improves learning processes and the best dosage for cognitive functioning and adapted school behavior differs.

Original findings from our research group shows that auditory noise has the possibility of enhancing cognitive performance in inattentive children without diagnosis as well as children with an ADHD diagnosis. One study found that the benefit of noise was in parity with, or even larger than, the benefit of pharmacological ADHD treatment on two cognitive tasks. The theory about noise benefit is thoroughly described by Sikström and Söderlund (2007). If auditory or visual noise, as suggested by the present project, could be a complement, or an alternative, to stimulant medication it could fundamentally change the treatment of ADHD and the school situation for those children.

The aims of this study are to: i) evaluate the effects of auditory white noise and visual white pixel noise on cognitive performance during two eye tracking tasks, ii) compare effects between ADHD and control groups ii) link noise benefit to specific traits.

Study Type  ICMJE Interventional
Study Phase  ICMJE Not Applicable
Study Design  ICMJE Allocation: Randomized
Intervention Model: Crossover Assignment
Intervention Model Description:

Patients will be recruited from Child and Adolescent Psychiatry in Lund. Typically developing children (TDC) will be recruited from schools.

All participants will perform a cross over control study. Participants will perform the entire test battery at one occasion, containing no noise, auditory white noise and visual white pixel noise (two levels). Participants in the ADHD group will perform the tests unmedicated. The order of the noise stimulation and no noise, as well as the order of the tasks, will be randomized over participants.

Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE
  • Attention Deficit Hyperactivity Disorder
  • Neurodevelopmental Disorders
Intervention  ICMJE
  • Device: Auditory noise stimulation
    Auditory white noise stimulation delivered at 78dB through earphones
  • Device: Visual noise stimulation
    Visual white pixel noise stimulation, backgound pixel noise visible at computer screen
Study Arms  ICMJE
  • No Intervention: No noise stimulation
    A prolonged fixation (PF) task and memory guided saccade (MGS) task will be performed without noise.
  • Active Comparator: Auditory white noise stimulation
    A prolonged fixation (PF) task and memory guided saccade (MGS) task will be performed in auditory white noise.
    Intervention: Device: Auditory noise stimulation
  • Active Comparator: Visual white pixel noise, 25%
    A prolonged fixation (PF) task and memory guided saccade (MGS) task will be performed in visual white pixel noise at 25%.
    Intervention: Device: Visual noise stimulation
  • Active Comparator: Visual white pixel noise, 50%
    A prolonged fixation (PF) task and memory guided saccade (MGS) task will be performed in visual white pixel noise at 50%.
    Intervention: Device: Visual noise stimulation
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Recruiting
Estimated Enrollment  ICMJE
 (submitted: September 21, 2023)
60
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE June 2025
Estimated Primary Completion Date June 2024   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Children and adolescents with a diagnosis of ADHD and control children without a diagnosis

Exclusion Criteria:

  • Intellectual disability
  • Psychosis
  • Severe depression or anxiety
  • The need of an interpreter to participate in the study
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 8 Years to 17 Years   (Child)
Accepts Healthy Volunteers  ICMJE Yes
Contacts  ICMJE
Contact: Emma Claesdotter-Knutsson, MD: PhD 0046768871765 emma.claesdotter-knutsson@skane.se
Listed Location Countries  ICMJE Sweden
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT06057441
Other Study ID Numbers  ICMJE 2023-02476-01
Has Data Monitoring Committee Not Provided
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD: No
Current Responsible Party Emma Claesdotter-Knutsson, Region Skane
Original Responsible Party Same as current
Current Study Sponsor  ICMJE Region Skane
Original Study Sponsor  ICMJE Same as current
Collaborators  ICMJE Lund University
Investigators  ICMJE
Principal Investigator: Emma Claesdotter-Knutsson, MD: PhD IKVL, Lund University
PRS Account Region Skane
Verification Date February 2024

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP